Continuation of Research and Development Activities
First written in FY2017-Q1. 13 of 25 entries say "Advanced", first in FY2017. Latest entry: FY2026.
115 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「R&D expenses for the consolidated fiscal year were ¥1,692 million. The purpose of research, key issues and research results for each segment are as follows.」
R&D expenses of ¥1,692 million were recorded, and the company developed and released CFT2 fiber-to-fiber recycling, new NaTech products, new KURASENSE models, QuickGene-AUTO12SⅡ and BBM-2000CL, among others. - FY2024AdvancedAnnual report
「R&D expenses for the consolidated fiscal year were ¥1,932 million. The purpose of research, key issues and research results for each segment are as follows.」
R&D expenses of ¥1,932 million were recorded, and the company reported the development and launch of Smartfit, L∞PLUS, NaTech, a track material monitoring system and QuickGene, among other products. - FY2024-Q2RestatedAnnual report
「The Group's total R&D expenditure for the six-month consolidated period was ¥932 million. There were no material changes in the status of the Group's R&D activities during the six-month consolidated period.」
R&D expenses of ¥932 million were recorded for the six-month period, with no material changes in the status of R&D activities. - FY2023-Q3AdvancedAnnual report
「The Group's total R&D expenditure for the nine-month consolidated period was ¥1,415 million. There were no material changes in the status of the Group's R&D activities during the nine-month consolidated period.」
R&D expenses of ¥1,415 million were recorded for the nine-month period, and R&D activities continued. - FY2023-Q2AdvancedAnnual report
「The Group's total R&D expenditure for the six-month consolidated period was ¥977 million.」
R&D expenses of ¥977 million were recorded for the six-month period, with no material changes in the status of R&D activities. - FY2022AdvancedAnnual report
「Research and development expenses for the consolidated fiscal year under review were ¥2,024 million. The objectives, key issues and results of research in each segment are as follows.」
R&D expenses increased from ¥1,924 million in the previous fiscal year to ¥2,024 million. The company reported development results including the expansion of Smartfit sales, the rollout of L∞PLUS to collected clothing, the establishment of a new NaTech production line, robot vision, semiconductor concentration meters and nucleic acid separation. - FY2022-Q3AdvancedAnnual report
「The Group's total R&D expenditure for the nine-month consolidated period was ¥1,479 million. There were no material changes in the status of the Group's R&D activities during the nine-month consolidated period.」
R&D expenses for the nine-month period totaled ¥1,479 million, and R&D activities continued. - FY2022-Q2AdvancedAnnual report
「The Group's total R&D expenditure for the six-month consolidated period was ¥977 million.」
R&D expenses of ¥977 million were recorded for the six-month period, with no material changes in the status of R&D activities. - FY2022-Q1AdvancedAnnual report
「The Group's total R&D expenditure for the three-month consolidated period was ¥483 million. There were no material changes in the status of the Group's R&D activities during the three-month consolidated period.」
While there were no material changes in the content of R&D activities, R&D expenses of ¥483 million were recorded. - FY2021-Q3Decrease in R&D expensesAnnual report
「The Group's total R&D expenditure for the nine-month consolidated period was ¥1,361 million. There were no material changes in the status of the Group's R&D activities during the nine-month consolidated period.」
While there were no material changes in the content of R&D activities, R&D expenses decreased to ¥1,361 million from ¥1,600 million in the same period of the previous year. - FY2021-Q1RestatedAnnual report
「The Group's total R&D expenditure for the three-month consolidated period was ¥458 million. There were no material changes in the status of the Group's R&D activities during the three-month consolidated period.」
R&D expenses of ¥458 million were recorded, with no material changes in the status of R&D activities. - FY2020AdvancedAnnual report
「R&D expenses for the consolidated fiscal year were ¥2,210 million. The purpose of research, key issues and research results for each segment are as follows.」
Annual R&D expenses of ¥2,210 million were recorded, and R&D continued in areas including smart factories, smart clothing, L∞PLUS, inspection equipment and biomedical applications. - FY2020-Q3RestatedAnnual report
「The Group's total R&D expenditure for the nine-month consolidated period was ¥1,600 million. There were no material changes in the status of the Group's R&D activities during the nine-month consolidated period.」
R&D expenses of ¥1,600 million were recorded, with no material changes in the status of R&D activities. - FY2020-Q2AdvancedAnnual report
「The Group's total R&D expenditure for the six-month consolidated period was ¥1,040 million. There were no material changes in the status of the Group's R&D activities during the six-month consolidated period.」
R&D expenses of ¥1,040 million were recorded, with no material changes in the status of R&D activities. - FY2020-Q1RestatedAnnual report
「The Group's total R&D expenditure for the three-month consolidated period was ¥506 million. There were no material changes in the status of the Group's R&D activities during the three-month consolidated period.」
R&D expenses of ¥506 million were recorded, with no material changes in the status of R&D activities. - FY2019-Q3AdvancedAnnual report
「The Group's total R&D expenditure for the nine-month consolidated period was ¥1,670 million. There were no material changes in the status of the Group's R&D activities during the nine-month consolidated period.」
R&D expenses of ¥1,670 million were recorded, with no material changes in the status of R&D activities. - FY2019-Q1RestatedAnnual report
「The Group's total R&D expenditure for the three-month consolidated period was ¥561 million. There were no material changes in the status of the Group's R&D activities during the three-month consolidated period.」
R&D expenses of ¥561 million were recorded, with no material changes in the status of R&D activities. - FY2018AdvancedAnnual report
「R&D expenses for the consolidated fiscal year were ¥2,038 million. The purpose of research, key issues and research results for each segment are as follows.」
R&D expenses increased from ¥1,970 million in the previous fiscal year to ¥2,038 million, and the company reported the launch of sales of new substrate inspection equipment and nucleic acid separation systems, among other products, as well as multiple new business projects. - FY2018-Q3RestatedAnnual report
「The Group's total R&D expenditure for the nine-month consolidated period was ¥1,506 million. There were no material changes in the status of the Group's R&D activities during the nine-month consolidated period.」
R&D expenses of ¥1,506 million were recorded, with no material changes in the status of R&D activities. - FY2018-Q2RestatedAnnual report
「The Group's total research and development expenditure for the cumulative second quarter was ¥957 million. There were no material changes in the status of the Group's research and development activities during the cumulative second quarter.」
The company recorded ¥957 million in research and development expenditure and stated that there were no material changes in the status of its research and development activities. - FY2018-Q1RestatedAnnual report
「The Group's total research and development expenditure for the cumulative first quarter was ¥470 million. There were no material changes in the status of the Group's research and development activities during the cumulative first quarter.」
The company recorded ¥470 million in research and development expenditure and stated that there were no material changes in the status of its activities. - FY2017AdvancedAnnual report
「Research and development expenditure for the consolidated fiscal year was ¥1,970 million. The objectives, key issues and research results for each segment are as follows.」
The company recorded ¥1,970 million in research and development expenditure and described the development and launch of sales of a heatstroke prevention risk management system, smart clothing, resource-recycling products, inspection equipment, a nucleic acid separation system and other products. - FY2017-Q3RestatedAnnual report
「The Group's total research and development expenditure for the cumulative third quarter was ¥1,449 million. There were no material changes in the status of the Group's research and development activities during the cumulative third quarter.」
Research and development expenditure totaled ¥1,449 million for the cumulative third quarter, with no material changes in the status of the activities. - FY2017-Q2RestatedAnnual report
「The Group's total research and development expenditure for the cumulative second quarter was ¥959 million. There were no material changes in the status of the Group's research and development activities during the cumulative second quarter.」
Research and development expenditure totaled ¥959 million for the first half, with no material changes in the status of the activities. - FY2017-Q1First statedAnnual report
「The Group's total research and development expenditure for the cumulative first quarter was ¥481 million. There were no material changes in the status of the Group's research and development activities during the cumulative first quarter.」
The company incurred ¥481 million in research and development expenditure and stated that there were no material changes in the status of its activities.